Industry Symposia :: IIGANN 2021

Virtual platform

Homepage > Partnership > Industry Symposia

Day 1 – 21 September 2021
10:30–11:30	Industry Symposium 2 – Otsuka The International Patient and Provider Voice in IgA Nephropathy Moderator: Jonathan Barratt Dana Rizk, Vivekanand Jha, Adrian Liew, Bonnie Schneider, Gisela Delgado, Malkia White An international roundtable discussion amongst nephrologists, patients, and a patient caregiver about living with, managing, supporting, and educating patients with IgA nephropathy. The symposium objectives include: amplifying the global voice for patients with IgA nephropathy, highlighting similarities and differences in each patient’s journey; increasing provider understanding of patients’ perspectives on living with IgA nephropathy and how these perspectives may differ internationally; understanding how providers can support patients with IgA nephropathy and which tools need to be added to their care armamentarium; identifying cross-cultural differences in IgA nephropathy diagnosis and understanding of the disease; facilitating understanding of patients’ management for IgA nephropathy, and identify current gaps in management.
15:00–15:30	Industry Symposium 6a – Novartis Heterogeneity in IgAN: Treatment challenges and unmet needs Chair: Smeeta Sinha Bart Maes, Loreto Gesualdo 15:00 Welcome note 15:03 Panel discussion: Disease progression among IgAN patients with different clinical characteristics 15:15 Panel discussion: Current treatment approaches and the unmet need for optimized therapies in IgAN 15:27 Thank you and summary An invitation to this symposium you can download here.
18:15–19:15	Industry Symposium 2 – Otsuka The International Patient and Provider Voice in IgA Nephropathy Moderator: Jonathan Barratt Dana Rizk, Vivekanand Jha, Adrian Liew, Bonnie Schneider, Gisela Delgado, Malkia White An international roundtable discussion amongst nephrologists, patients, and a patient caregiver about living with, managing, supporting, and educating patients with IgA nephropathy. The symposium objectives include: amplifying the global voice for patients with IgA nephropathy, highlighting similarities and differences in each patient’s journey; increasing provider understanding of patients’ perspectives on living with IgA nephropathy and how these perspectives may differ internationally; understanding how providers can support patients with IgA nephropathy and which tools need to be added to their care armamentarium; identifying cross-cultural differences in IgA nephropathy diagnosis and understanding of the disease; facilitating understanding of patients’ management for IgA nephropathy, and identify current gaps in management.
19:20–20:20	Industry Symposium 1 – Calliditas IgA nephropathy – Seeing the Bigger Picture Jonathan Barratt: Gut-kidney pathophysiology and evidence for the role of the gut in IgAN Richard Lafayette: Proteinuria and eGFR as endpoints and how they translate into meaningful patient outcomes

Day 2 – 22 September 2021
09:05–10:05	Industry Symposium 3 – Chinook Novel Targets and Therapeutics for IgAN Management Richard Lafayette: Pathogenesis of IgAN Adrian Liew: Clinical rationale for a potent and selective ETA blocker for the treatment of IgAN Jonathan Barrat: Unmet need and rationale for the development of anti-APRIL agents in IgAN
10:20–11:20	Industry Symposium 4 – Travere The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and Proteinuria Jonathan Barratt: Introduction and setting the scene Matthias Barton: Charting the Course of CKD – Endothelin-1 and Angiotensin II: Brothers in Arms Jürgen Floege: Signs in the Clinical Journey to CKD – Proteinuria in IgA Nephropathy Jonathan Barratt: Changing the Course – The Evolving Treatment Landscape in IgA Nephropathy An invitation to this symposium you can download here.
14:50–15:20	Industry Symposium 6b – Novartis The important role of the alternative complement pathway in IgAN Chair: Bart Maes Lisa Willcocks 14:50 Opening remarks 14:51 Presentation: The role of the complement system, specifically the alternative pathway, in the pathogenesis of IgAN 15:03 Presentation: The current treatment paradigm in IgAN and the unmet needs 15:15 Closing remarks An invitation to this symposium you can download here.
18:05–19:05	Industry Symposium 4 – Travere The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and Proteinuria Jonathan Barratt: Introduction and setting the scene Matthias Barton: Charting the Course of CKD – Endothelin-1 and Angiotensin II: Brothers in Arms Jürgen Floege: Signs in the Clinical Journey to CKD – Proteinuria in IgA Nephropathy Jonathan Barratt: Changing the Course – The Evolving Treatment Landscape in IgA Nephropathy An invitation to this symposium you can download here.
19:10–20:10	Industry Symposium 3 – Chinook Novel Targets and Therapeutics for IgAN Management Richard Lafayette: Pathogenesis of IgAN Adrian Liew: Clinical rationale for a potent and selective ETA blocker for the treatment of IgAN Jonathan Barrat: Unmet need and rationale for the development of anti-APRIL agents in IgAN

Day 3 – 23 September 2021
09:05–10:05	Industry Symposium 5 – Omeros Emerging Evidence on the Role of Lectin Pathway Inhibition in the Management of IgAN Objective: To enhance awareness about the pathophysiology of IgAN and educate on the role of the lectin pathway of complement using emerging clinical evidence. Vladimir Tesar: IgAN Clinical Review: Pathophysiology and Treatment Landscape Richard Lafayette: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition Hong Zhang: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition (Part 2) Jonathan Barratt: Emerged Clinical Data from Phase 2 Interim Analysis and Description of Phase 3 ARTEMIS-IGAN Trial An invitation to this symposium you can download here.
14:35–15:35	Industry Symposium 5 – Omeros Emerging Evidence on the Role of Lectin Pathway Inhibition in the Management of IgAN Objective: To enhance awareness about the pathophysiology of IgAN and educate on the role of the lectin pathway of complement using emerging clinical evidence. Vladimir Tesar: IgAN Clinical Review: Pathophysiology and Treatment Landscape Richard Lafayette: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition Hong Zhang: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition (Part 2) Jonathan Barratt: Emerged Clinical Data from Phase 2 Interim Analysis and Description of Phase 3 ARTEMIS-IGAN Trial An invitation to this symposium you can download here.

CONTACT

Symposium Secretariat

GUARANT International spol. s r.o.
Českomoravská 19
190 00 Prague 9
Czech Republic

+420 284 001 444
iigann2021@guarant.cz